These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 14645446)

  • 1. Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to oxaliplatin combination chemotherapy: implications for tumor marker monitoring and guidelines.
    Sørbye H; Dahl O
    J Clin Oncol; 2003 Dec; 21(23):4466-7. PubMed ID: 14645446
    [No Abstract]   [Full Text] [Related]  

  • 2. [A case of local recurrence of colon cancer responding to chemotherapy with low-dose oxaliplatin, 5-FU and l-LV].
    Seki H; Kurihara E; Iwata K; Saito J
    Gan To Kagaku Ryoho; 2007 Aug; 34(8):1291-3. PubMed ID: 17687216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [FOLFOX].
    Mishima H; Ikenaga M; Tsujinaka T; Yasui M; Kashiwazaki M; Miyazaki M; Hirao M; Fujitani K; Nakamori S
    Gan To Kagaku Ryoho; 2006 Jul; 33(7):911-4. PubMed ID: 16835479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I/II study of oxaliplatin with weekly bolus fluorouracil and high-dose leucovorin (ROX) as first-line therapy for patients with colorectal cancer.
    Yamada Y; Ohtsu A; Boku N; Miyata Y; Shimada Y; Doi T; Muro K; Muto M; Hamaguchi T; Mera K; Yano T; Tanigawara Y; Shirao K
    Jpn J Clin Oncol; 2006 Apr; 36(4):218-23. PubMed ID: 16684860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A case of metastatic colon cancer to paraaortic lymph nodes and liver treated successfully with oxaliplatin combination chemotherapy].
    Hoshina K; Kobayashi I; Kuwano H; Kurita M; Shida D; Shinkai H; Miyashita M
    Gan To Kagaku Ryoho; 2007 Jul; 34(7):1135-7. PubMed ID: 17637557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxaliplatin in the treatment of colorectal cancer.
    Kim GP; Erlichman C
    Expert Opin Drug Metab Toxicol; 2007 Apr; 3(2):281-94. PubMed ID: 17428157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group.
    Giacchetti S; Bjarnason G; Garufi C; Genet D; Iacobelli S; Tampellini M; Smaaland R; Focan C; Coudert B; Humblet Y; Canon JL; Adenis A; Lo Re G; Carvalho C; Schueller J; Anciaux N; Lentz MA; Baron B; Gorlia T; Lévi F;
    J Clin Oncol; 2006 Aug; 24(22):3562-9. PubMed ID: 16877722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX-4) as salvage chemotherapy in patients with pretreated colorectal cancer.
    Shitara K; Munakata M; Muto O; Kasai M; Okada R; Mitobe S; Sakata Y
    Gan To Kagaku Ryoho; 2007 Jul; 34(7):1079-84. PubMed ID: 17637544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update: NCCN colon and rectal cancer clinical practice guidelines.
    Kiel K; Engstrom PF
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 3():S-14-8. PubMed ID: 23570093
    [No Abstract]   [Full Text] [Related]  

  • 10. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
    Kim SH; Kwon HC; Oh SY; Lee DM; Lee S; Lee JH; Roh MS; Kim DC; Park KJ; Choi HJ; Kim HJ
    Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxaliplatin, 5-fluorouracil, and leucovorin as second-line treatment for advanced pancreatic cancer.
    Novarino A; Satolli MA; Chiappino I; Giacobino A; Bellone G; Rahimi F; Milanesi E; Bertetto O; Ciuffreda L
    Am J Clin Oncol; 2009 Feb; 32(1):44-8. PubMed ID: 19194124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy of m-FOLFOX6 therapy for colorectal cancer in elderly patients].
    Young Kim W; Maeda K; Noda E; Fukunaga S; Inoue T; Kaizaki R; Shinto O; Wada K; Nakano T; Hirakawa K
    Gan To Kagaku Ryoho; 2007 Nov; 34(11):1833-6. PubMed ID: 18030018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.
    Tournigand C; Cervantes A; Figer A; Lledo G; Flesch M; Buyse M; Mineur L; Carola E; Etienne PL; Rivera F; Chirivella I; Perez-Staub N; Louvet C; André T; Tabah-Fisch I; de Gramont A
    J Clin Oncol; 2006 Jan; 24(3):394-400. PubMed ID: 16421419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer.
    Ducreux M; Ychou M; Laplanche A; Gamelin E; Lasser P; Husseini F; Quenet F; Viret F; Jacob JH; Boige V; Elias D; Delperro JR; Luboinski M;
    J Clin Oncol; 2005 Aug; 23(22):4881-7. PubMed ID: 16009952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity and toxicity of oxaliplatin and bolus fluorouracil plus leucovorin in pretreated colorectal cancer patients: a phase II study.
    Ferraresi V; Giampaolo MA; Gabriele A; Mansueto G; Buccilli A; Giannarelli D; Ciccarese M; Gamucci T
    J Exp Clin Cancer Res; 2005 Jun; 24(2):187-96. PubMed ID: 16110750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Carcinoembryonic antigen, CEA, in colorectal cancer. An insensitive marker which may be excluded from follow-ups].
    Wählby L
    Lakartidningen; 1997 Apr; 94(18):1716-8. PubMed ID: 9182180
    [No Abstract]   [Full Text] [Related]  

  • 17. Activity and toxicity of oxaliplatin plus raltitrexed in 5-fluorouracil refractory metastatic colorectal adeno-carcinoma.
    Laudani A; Gebbia V; Leonardi V; Savio G; Borsellino N; Cusimano MP; Calabria C; Stefano R; Agostara B
    Anticancer Res; 2004; 24(2C):1139-42. PubMed ID: 15154638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An EORTC phase I study of Bortezomib in combination with oxaliplatin, leucovorin and 5-fluorouracil in patients with advanced colorectal cancer.
    Caponigro F; Lacombe D; Twelves C; Bauer J; Govaerts AS; Marréaud S; Milano A; Anthoney A
    Eur J Cancer; 2009 Jan; 45(1):48-55. PubMed ID: 18809314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is oxaliplatin combined with weekly bolus 5-fluorouracil and leucovorin an option for stage II and III colon cancer?
    Twelves C
    Nat Clin Pract Oncol; 2008 Feb; 5(2):72-3. PubMed ID: 18030299
    [No Abstract]   [Full Text] [Related]  

  • 20. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
    Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
    J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.